Pathophysiology of retinal neovascularization

Therapy for Ocular Angiogenesis: Principles and Practice

Volumn , Issue , 2012, Pages

  Frank, Robert N ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b HUTZEL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971554235     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Engerman RL, Pfaffenbach D, Davis MD. Cell turnover of capillaries. Lab Invest. 1967;17:738-743.
2. Chan-Ling T. Vasculogenesis and angiogenesis in formation of the human retinal vasculature. In: Penn JS, ed. Retinal and Choroidal Angiogenesis. Dordrecht, the Netherlands: Springer; 2008:chap 6, 119-138.
3. Fruttiger M. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. Invest Ophthalmol Vis Sci. 2002;43:522-527.
4. Gariano RF. Cellular mechanisms in retinal vascular development. Prog Retin Eye Res. 2003;22:295-306.
5. Kramerov AA, Saghizadeh M, Caballero S, et al. Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites. Mol Cell Biochem. 2008;316:177-186.
6. Sengupta N, Caballero S, Mames RN, et al. The role of adult bone marrow-derived stem cells in choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:4908-4913.
7. Ljubimov AV, Caballero S, Aoki AM, et al. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol Vis Sci. 2004;45:4583-4591.
8. Campochiaro PA and the First ARVO/Pfizer Working Group. Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest Ophthalmol Vis Sci. 2006;47:462-474.
9. Ferrara N. VEGF and EG-VEGF. Invest Ophthalmol Vis Sci 2006;47(suppl 1):462-474. Available online at: http://www.iovs.org/cgi/data/47/2/462/DC1/10
10. Henkind P. Ocular neovascularization. Am J Ophthalmol. 1978;85:287-301.
11. Ashton N. Oxygen and the retinal blood vessels. Trans Ophthalmol Soc U K. 1980;100:359-362.
12. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
13. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
14. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36-47.
15. Frank RN, Amin R, Kennedy A, et al. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia. Arch Ophthalmol. 1997;115:136-147.
16. Zahs K, Esguerra M. Glial cells in the developing retina. In: Retinal Development. Sernagor E, Eglen S, Harris B, Wong R, eds. Cambridge, UK: Cambridge University Press; 2006: 172-192.
17. Witmer AN, Blaauwgeers HG, Weich HA, et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci. 2002;43:849-857.
18. Provis JM. Development of the primate retinal vasculature. Prog Retin Eye Res. 2001;20:799-821.
19. Semenza GL. Hypoxia and HIF-1. Invest Ophthalmol Vis Sci. 2006;47(suppl 12):462-474. Available online at http://www.iovs.org/cgi/data/47/2/462/DC1/20
20. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
21. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 1998;12:149-162.
22. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219-1224.
23. Lu M, Amano S, Miyamoto K, et al. Insulin-induced vascular endothelial growth factor expression in retina. Invest Ophthalmol Vis Sci. 1999;40:3281-3286.
24. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98:1667-1675.
25. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-365.
26. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem. 2004;264:85-97.
27. Al-Shabrawey M, Rojas M, Sanders T, et al. Role of NADPH oxidase in retinal vascular inflammation. Invest Ophthalmol Vis Sci. 2008;49:3239-3244.
28. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
29. DCCT Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes. 1997;46:1829-1839.
30. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320:1161-1165.
31. Arar NH, Freedman BI, Adler SG, et al. Family Investigation of Nephropathy and Diabetes Research Group. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49:3839-3845.
32. Al-Kateb H, Mirea L, Xie X et al. and the DCCT/EDIC Research Group.Multiple variants in vascular endothelial growth factor (VEGFA) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes. 2007;56:2161-2168.
33. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3611-3616.
34. Errera FI, Canani LH, Silva ME, et al. Functional vascular endothelial growth factor -634G>C SNP is associated with proliferative diabetic retinopathy: a case-control study in a Brazilian population of European ancestry. Diabetes Care. 2007;30:275-279.
35. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480-1487.
36. Adamis AP, Miller JW, Bernal M-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118:445-450.
37. Shimada H, Akaza E, Yuzawa M, et al. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50:2953-2955.
38. Khurana RN, Do DV, Nguyen QD. Anti-VEGF therapeutic approaches for diabetic macular edema. Int Ophthalmol Clin. 2009;49:109-119.
39. Aiello LP. Targeting intraocular neovascularization and edema-one drop at a time. N Engl J Med. 2008;359:967-969.
40. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
41. Brown LF, Detmar M, Claffey K, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997;79:233-269.
42. Dvorak HF. Discovery of vascular permeability factor (VPF). Exp Cell Res. 2006;312:522-526.
43. Frank RN. Treating diabetic retinopathy by inhibiting growth factor pathways. Curr Opin Investig Drugs. 2009;10: 327-335.
44. Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor (VEGF)-induced permeability. J Biol Chem. 2009 May 28; [Epub ahead of print].
45. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274:23463-23467.
46. Hoffmann S, He S, Ehren M, et al. MMP-2 and MMP-9 secretion by RPE is stimulated by angiogenic molecules found in choroidal neovascular membranes. Retina. 2006;26:454-461.
47. Ottino P, Finley J, Rojo E, et al. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: involvement of cytosolic phospholipase A2 activity. Mol Vis. 2004;10:341-350.
48. Giebel SJ, Menicucci G, McGuire PG, et al. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest. 2005;85:597-607.
49. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci. 1999;40:809-813.
50. Das A, McLamore A, Song W, et al. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol. 1999;117:498-503.
51. Chantelau E, Kohner EM. Why some cases of retinopathy worsen when diabetic control improves. Br Med J. 1997;315:1105-1106.
52. Wang Q, Dills DG, Klein R, et al. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes. 1995;44:161-164.
53. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-5182.
54. Campochiaro P. Ocular neovascularization. Invest Ophthalmol Vis Sci. 2006;47(suppl 21):462-474. Available online at: http://www.iovs.org/cgi/data/47/2/462/DC1/7
55. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:393-402.
56. Das A, Fanslow W, Cerretti D, et al. Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization. Lab Invest. 2003;83:1637-1645.
57. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Ryan SJ, Schachat AP, Wilkinson CP, Hinton D, eds. Retina, 4th ed. London: Elsevier; 2006:chap 66, 1240-1270.
58. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
59. Tong Z, Yang Z, Patel S et al, and the Genetics of Diabetes and Diabetic Complication Study Group. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A. 2008;105:6998-7003.
60. Kuwabara T, Cogan DG. Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol. 1963;69: 492-502.
61. Kern TS. Animal models of diabetic retinopathy. In: Penn JS, ed. Retinal and Choroidal Angiogenesis. Dordrecht, the Netherlands: Springer; 2008:chap 4, 81-102.
62. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 1996;97:2883-2890.
63. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783-791.
64. Kohner EM, Henkind P. Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy. Am J Ophthalmol. 1970;69:403-414.
65. Orlidge A, D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol. 1987;105:1455-1462.
66. Antonelli-Orlidge A, Saunders KB, Smith SR, et al. An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A. 1989;86:4544-4548.
67. Lindahl P, Johansson BR, Levéen P, et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 77:242-245.
68. Betsholtz C, Lindblom P, Gerhardt H. Role of pericytes in vascular morphogenesis. EXS. 2005;94:115-125.
69. Dawson DW, Volpert OV, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
70. Steele FR, Chader GJ, Johnson LV, et al. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A. 1993;90:1526-1530.
71. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999;155:421-428.
72. Esser S, Wolburg K, Wolburg H, et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998;140:947-959.
73. Becerra SP, Fariss RN, Wu YQ, et al. Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res. 2004;78:223-234.
74. Eliassi-Rad B, Green WR. Histopathologic study of presumed parafoveal telangiectasis. Retina. 1999;19:332-335.
75. Lafaut BA, Aisenbrey S, Vanden Broecke C, et al. Clinicopathological correlation of deep retinal vascular anomalous complex in age related macular degeneration. Br J Ophthalmol. 2000;84:1269-1274.
76. Yannuzzi LA, Negrão S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416-434.